



NDA 70-101

FEB 22 1986

Biocraft Laboratories, Inc.  
Attention: Harvey Richards  
P.O. Box 200  
Elmwood Park, New Jersey 07407

Gentlemen:

Reference is made to your abbreviated new drug application dated November 26, 1984, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Disopyramide Phosphate Capsules USP, 100 mg.

Reference is made to your amendments dated February 15, and February 20, 1985 (FPL).

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

This Administration should be advised of any change in the marketing status of this drug.


**For Initial Campaigns:** We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Please do not use Form FD-2253 for this initial submission.

**For Subsequent Campaigns:** We call your attention to Regulation 21 CFR 310.300 (b)(3) which requires that materials for any subsequent advertising or promotional campaign, at the time of their initial use, be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253. A copy of Form FD-2253 is enclosed for your convenience.

-Page 2-

The enclosures summarize the conditions relating to the approval of this abbreviated application.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Marvin Seife". The signature is written in a cursive style with a large, looped initial "M".

Marvin Seife, M.D.

Director

Division of Generic Drugs

Office of Drug Standards

Center for Drugs and Biologics

Enclosures:

Conditions of Approval of a New Drug Application

Records & Reports Requirements

Form FD 2253